[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"opioid-consumption-postoperative\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:opioid-consumption-postoperative":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,43,78,109,142,177,205,236,266,295,326,359,382,408],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100644628","phase-4-precision-pain-management---a-randomized-clinical-trial-assessing-the-efficacy-of-suzetrigine-on-postoperative-analgesia-among-surgical-patients-at-higher-risk-for-persistent-postoperative-opioid-use-pou-100644628",false,"NCT07672015","Precision Pain Management - A Randomized Clinical Trial Assessing the Efficacy of Suzetrigine on Postoperative Analgesia Among Surgical Patients at Higher Risk for Persistent Postoperative Opioid Use (POU)","Inclusion Criteria:\n\n* Patients who are identified as high-risk for POU as calculated by our SurgNet-POU predictive deep learning model. The probability threshold will be set at \\~\\> 0.25. Potential participants will be screened prior to surgery by incorporating their electronic health record data in to the model.\n* Patients undergoing major orthopedic surgery (hip arthroplasty, knee arthroplasty, shoulder arthroplasty, joint arthroscopy, foot\u002Fankle surgery, upper extremity fracture surgery, spine surgery), breast surgery (mastectomy, breast reconstruction), gynecological surgery (hysterectomy, myomectomy), or abdominal surgery.\n* Adult patients of at least 18 years of age\n* Has the capacity to consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Incarceration\n* Patients with a previous history of opioid use disorder.\n* Patients on fentanyl transdermal patch, methadone, and\u002For buprenorphine.","ALL","18 Years",{"count":18,"type":19},100,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","The purpose of the study is to investigate the efficacy of suzetrigine for treatment of acute postoperative pain among surgical patients identified as high risk for persistent postoperative opioid use (POU). Using a validated artificial intelligence predictive model (termed SurgNet-POU) developed by the PI, electronic health record (EHR) data will be queried from all prospective surgical patients undergoing orthopedic surgery and inputted into the model to predict risk of POU (defined as requiring opioids ≥ 3 months after surgery). Those identified as high risk by the SurgNet-POU will be eligible candidates for this study. Suzetrigine (Vertex Pharmaceuticals) is an FDA-approved non-opioid oral analgesic that acts as a selective Nav1.8 sodium channel blocker. It has been shown to have efficacy in post-surgical pain and has compared favorably to placebo and similar to some opioids, without the risk of addiction or other adverse events related to opioids. Consented participants will be randomized to one of two arms: (1) standard care (termed standard care) defined as usual prescribing outpatient opioid analgesic protocols per surgical team; versus (2) standard care combined with 14-day regimen of suzetrigine. Those randomized to the suzetrigine arm will receive 100mg suzetrigine PO \\~ 1-2 hours prior to surgery and take 50mg po twice a day for 14 days postoperatively. The primary outcome will be total opioid consumption over 14 days postoperatively. Secondary outcomes include average, highest and lowest pain scores at 7, 14, 30, and 90 days after surgery; and opioid consumption at 7, 30, and 90 days after surgery.",[25],"Opioid Consumption, Postoperative",[27,28,29],"persistent postoperative opioid use","artificial intelligence","postoperative pain","NOT_YET_RECRUITING","2026-06-26",{"date":33,"type":34},"2026-06-30","ACTUAL",{"date":36,"type":19},"2026-06",{"date":38,"type":19},"2027-06",{"name":40,"class":41},"University of California, San Diego","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":16,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":20,"phases":55,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":42},"100641134","spsip-block-for-pain-control-after-breast-reduction-surgery-100641134","NCT07657949","SPSIP Block for Pain Control After Breast Reduction Surgery","Effect of Ultrasound-Guided Serratus Posterior Superior Intercostal Plane Block on Opioid Consumption After Reduction Mammaplasty: A Prospective Randomized Controlled Trial","SPSIP-RM","Inclusion Criteria:\n\n* Female participants aged 18 to 65 years\n* Scheduled for elective bilateral reduction mammaplasty\n* Planned surgery under general anesthesia\n* American Society of Anesthesiologists physical status class I to III\n* Planned postoperative clinical follow-up for the first 24 hours after surgery\n* Able to understand and report pain using the 0 to 10 Numeric Rating Scale\n* Able to provide written informed consent for study participation\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to local anesthetic drugs\n* Contraindication to regional anesthesia or fascial plane block\n* Coagulopathy or clinically significant bleeding disorder\n* Use of anticoagulant or antiplatelet medication that prevents safe block application\n* Infection at the planned block injection site\n* Chronic opioid use, chronic pain syndrome, or regular analgesic use that may affect postoperative pain assessment\n* Revision breast surgery\n* Planned major additional surgical procedure other than reduction mammaplasty\n* Pregnancy or lactation\n* Unable to reliably report pain scores","FEMALE","65 Years",{"count":54,"type":19},80,[56],"NA","The goal of this clinical trial is to learn whether an ultrasound-guided serratus posterior superior intercostal plane block (SPSIP block) can lower the need for opioid pain medicine after breast reduction surgery.\n\nThe main question it aims to answer is: Does adding an SPSIP block to standard anesthesia and pain treatment lower opioid use during the first 24 hours after surgery? Researchers will compare participants who receive standard anesthesia and pain treatment with participants who receive standard anesthesia and pain treatment plus an SPSIP block.\n\nParticipants will:\n\n* Have planned bilateral breast reduction surgery under general anesthesia\n* Be randomly assigned to the SPSIP block group or the control group\n* Receive standard local anesthetic infiltration during surgery and standard pain treatment after surgery\n* Have their pain score and pain medicine use recorded during the first 24 hours after surgery\n* Be followed for safety and complications for 30 days after surgery",[59,60,61,62,25],"Postoperative Pain Breast Reduction","Mammaplasty","Analgesia","Nerve Block",[64,65,66,67,68],"Serratus posterior superior intercostal plane block","Ultrasound-guided regional anesthesia","Reduction mammaplasty","Breast reduction surgery","Postoperative pain","2026-06-14",{"date":71,"type":34},"2026-06-18",{"date":73,"type":19},"2026-08-01",{"date":75,"type":19},"2027-08-31",{"name":77,"class":41},"Cumhuriyet University Hospital",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":15,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":20,"phases":88,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100642199","phase-3-assessing-suzetrigine-for-pain-reduction-following-ureteroscopic-surgery-100642199","NCT07654296","Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery","Multimodal Analgesia Pathway Assessing Role of Suzetrigine for the Reduction of Opioid Use Following Ureteroscopic Surgery","Inclusion Criteria:\n\n* Patients undergoing ureteroscopy between ages 21 to 80 at BWFH (Brigham \\& Women's Faulkner Hospital) by one of the department's high volume endoscopic surgeons. Patient who are or not pre-stented prior to surgery will be included (these will be assessed via stratification within a secondary analysis).\n* Patients able to consent for their own medical care (i.e. consent able to be obtained directly from patient and does not require a healthcare proxy or guardian)\n\nExclusion Criteria:\n\n* Regular opioid use prior to surgery or significant substance abuse concerns.\n* Inability of patient to provide their own consent (i.e. lack capacity).","21 Years","80 Years",{"count":18,"type":19},[89],"PHASE3","Urologic surgery has advanced with new technologies to allow less invasive management of common afflictions such as kidney stones, these procedures are notoriously painful as the ureter must be dilated to accommodate any instruments, and a ureteral stent is often left following surgery to allow for adequate healing. Unfortunately, stents are poorly tolerated by a significant number of patients, with up to 100% complaining of bothersome pain and 10% of patients with unplanned healthcare visits. Further complicating kidney stone management is the frequency of concurrent chronic kidney disease (CKD) or acute kidney injury (AKI) that prohibits many patients from taking NSAIDs which limits pain management options. There is now a push to treat these patients with multimodal analgesia to provide better care and reduce opioid use. Suzetrigine is a new a first-in-class selective inhibitor of the NaV1.8 sodium channel that functions as a non-opioid analgesic developed to treat acute pain and neuropathic pain. This study assesses the addition of suzetrigine to standard-of-care multimodal analgesia. We hypothesize a demonstrated decrease in opioid use, decrease Emergency Room visits within 30 days, decrease the number of unplanned care encounters.",[25,92,93,94,95],"Multimodal Analgesia","Ureteroscopy","Ureteral Stents","Ureteral Stent-Related Symptoms",[92,97,98,99],"Postoperative Opioid Consumption","ureteroscopy","ureteral stents","2026-06-12",{"date":102,"type":34},"2026-06-17",{"date":73,"type":19},{"date":105,"type":19},"2027-03-31",{"name":107,"class":41},"Brigham and Women's Hospital",2,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":20,"phases":120,"briefSummary":121,"conditions":122,"keywords":125,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":42},"100643344","transauricular-vagus-nerve-stimulation-frequencies-for-postoperative-pain-100643344","NCT07633444","Transauricular Vagus Nerve Stimulation Frequencies for Postoperative Pain","Effects of Different Frequencies of Transauricular Vagus Nerve Stimulation on Postoperative Pain: A Randomized, Double-Blind, Sham-Controlled Trial With Preoperative and Postoperative Sessions","TVNS-PAIN","Inclusion Criteria:\n\n* Adults aged 18 to 59 years.\n* Undergoing elective abdominal or urologic surgery.\n* American Society of Anesthesiologists (ASA) physical status I-III.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* History of neurological disorders.\n* History of psychiatric disorders.\n* Inability to understand study procedures.\n* Pregnancy.\n* Cognitive impairment.\n* Communication difficulties that interfere with study assessments.\n* Auricular dermatitis or skin lesions at the stimulation site.\n* Pre-existing cardiac arrhythmia.\n* Chronic opioid use.\n* Implanted electronic medical devices, including pacemakers.","59 Years",{"count":119,"type":19},174,[56],"The goal of this clinical trial is to learn whether different frequencies of transauricular vagus nerve stimulation (tVNS) can reduce postoperative pain and opioid consumption in adults undergoing abdominal or urologic surgery. It will also evaluate the effects of tVNS on recovery quality, autonomic function, and treatment safety. The main questions it aims to answer are:\n\nDoes transauricular vagus nerve stimulation reduce postoperative opioid consumption during the first 24 hours after surgery? Do different stimulation frequencies (high-frequency and low-frequency tVNS) produce different effects on postoperative pain and autonomic responses? Is transauricular vagus nerve stimulation safe and well tolerated in surgical patients?\n\nResearchers will compare high-frequency tVNS, low-frequency tVNS, and sham stimulation (inactive stimulation) to determine their effects on postoperative pain and opioid requirements.\n\nParticipants will:\n\nBe randomly assigned to receive high-frequency tVNS, low-frequency tVNS, or sham stimulation.\n\nReceive two 30-minute stimulation sessions, one before anesthesia and one after surgery in the post-anesthesia care unit.\n\nUndergo assessments of postoperative pain, opioid consumption, need for rescue analgesics, postoperative nausea and vomiting, heart rate changes, and quality of recovery.\n\nBe monitored for adverse events related to the intervention during the study period.\n\nA total of 174 participants will be enrolled in this single-center, randomized, double-blind, sham-controlled clinical trial.",[123,124,25],"Postoperative Pain","Postoperative Nausea and Vomiting (PONV)",[123,126,127,128,129,130,131],"Transauricular Vagus Nerve Stimulation","tVNS","Neuromodulation","Opioid Consumption","Pain Management","Randomized Controlled Trial","RECRUITING","2026-06-07",{"date":135,"type":34},"2026-06-10",{"date":137,"type":19},"2026-06-01",{"date":139,"type":19},"2026-12-04",{"name":141,"class":41},"Federal University of Bahia",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":149,"sex":15,"minAge":16,"maxAge":86,"enrollmentInfo":150,"targetDuration":4,"studyType":20,"phases":152,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":42},"100610370","phase-3-suzetrigine-in-total-hip-arthroplasty-100610370","NCT07226700","Suzetrigine in Total Hip Arthroplasty","A Randomized, Placebo-controlled, Double-blind Trial of Suzetrigine in Total Hip Arthroplasty","Inclusion Criteria:\n\n* Patients undergoing primary THA (posterior approach) with participating surgeons\n* Age 18 to 80 years old\n* Planned discharge to home\n* Planned use of neuraxial anesthesia\n* American Society of Anesthesiologists (ASA) Physical Status 1 - 3\n\nExclusion Criteria:\n\n* ASA greater than 3\n* Chronic opioid use (daily MME of greater than 30 mg for at least 3 months and within 1 month of surgery)\n* History of chronic pain syndromes or uncontrolled pain (i.e. complex regional pain syndrome, fibromyalgia, implanted spinal cord stimulator)\n* History of QT prolongation\n* Presence of automated implantable cardioverter defibrillator, pacemaker or cardiac resynchronization device\n* Evidence of misuse, aberrant use, or addiction to alcohol or an illicitly used drug of abuse, or had a positive test for drugs of abuse\n* Inability to comply with any component of the study protocol\n* Younger than 18 or greater than 80 years old at the time of enrollment\n* Patient already on Suzetrigine\n* Allergy or contraindication to Suzetrigine or excipients (eg moderate to severe liver disease\u002FChild Pugh B or C, use of strong CYP3 inhibitors or inducers)\n* Contraindications to neuraxial anesthesia or any other part of the study protocol\n* Participation in another investigational drug or device study\n* Pregnancy",true,{"count":151,"type":19},210,[89],"Total hip and knee joint replacements are among the most common and painful orthopedic procedures performed worldwide, often requiring intensive analgesia to support early ambulation and recovery. Despite widespread use of multimodal regimens, many patients still rely on opioids, which can cause sedation, nausea, constipation, and long-term dependency. Evaluating Suzetrigine in this high-need population may improve recovery trajectories, reduce opioid consumption, and support enhanced recovery protocols. Given the growing surgical volume and the emphasis on opioid-sparing strategies, rigorous investigation of Suzetrigine's efficacy in joint replacement is of high clinical value. In this study, patients undergoing primary total hip replacement will be randomized to receive either Suzetrigine or placebo for seven days, with the loading dose administered prior to surgery. The primary outcome is cumulative 48-hour opioid consumption in oral morphine equivalents starting from entry into the post-anesthesia care unit (PACU).",[155,156,157,158,159,160,161,130,162,163,164,165,25,92,131,166,167],"Total Hip Arthroplasty (THA)","Total Hip Arthroplasty \\(THA\\)","Total Hip Replacement","Total Hip Replacement Surgery","Total Hip Replacements","Total Hip Replacement Arthroplasty","Suzetrigine","Pain","Nav 1.8","JOURNAVX","Opioid Cessation","Randomized Controlled Study","Randomized Controlled Trials","2026-06-02",{"date":170,"type":34},"2026-06-03",{"date":172,"type":34},"2025-11-03",{"date":174,"type":19},"2028-11-01",{"name":176,"class":41},"Hospital for Special Surgery, New York",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":185,"minAge":186,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":20,"phases":189,"briefSummary":190,"conditions":191,"keywords":195,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":108},"100625777","phase-3-robotic-opioid-free-prostatectomy-enhanced-strategy-ropes-100625777","NCT07427043","Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)","Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES): Implementation of an Opioid-free Multimodal Analgesia Discharge Pathway","ROPES","Inclusion Criteria:\n\n* Men ≥45 years old\n* Undergoing Robotic Assisted Laparoscopic Prostatectomy (RALP) at BWH or BWFH\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Chronic kidney disease (baseline Cr \\>1.3)\n* NSAID contraindication\u002Fallergy\n* Regular opioid use or substance abuse prior to surgery\n* Inability to provide their own consent\n* Deviation from standard surgical practice for RALP (e.g. major complication requiring operative intervention that would result in patient no longer being considered a routine case)","MALE","45 Years",{"count":188,"type":19},300,[89],"This prospective, interventional, open-label, phase 3 randomized study evaluates a multimodal analgesia discharge pathway to reduce automatic opioid prescribing following routine robotic-assisted laparoscopic prostatectomy (RALP). Patients are counseled on post-operative pain management and then may opt into or out of the study with randomization to discharge prescriptions including (A) multimodal plan with additional automatic opioid prescription or (B) multimodal plan alone and instruction to call phone line to request opioid prescription if pain management is insufficient. Additionally, a cohort of historical controls prior to implementation of the study is also prospectively assessed as a pre-study baseline. The primary outcome is postoperative opioid consumption. Secondary outcomes include bowel function recovery, unplanned care encounters including emergency department visits or postoperative phone calls, and same-day discharge rates.",[25,92,192,193,194],"Robotic Assisted Laparoscopic Surgery","Robotic Assisted Laparoscopic Radical Prostatectomy","Prostate Cancer",[92,193,97,196,192],"Localized Prostate Cancer","2026-05-20",{"date":199,"type":34},"2026-05-22",{"date":201,"type":34},"2026-03-01",{"date":203,"type":19},"2027-04-30",{"name":107,"class":41},{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":15,"minAge":213,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":20,"phases":217,"briefSummary":218,"conditions":219,"keywords":222,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":42},"100640623","rectus-sheath-block-versus-transversus-abdominis-plane-block-for-analgesia-in-laparoscopic-bariatric-surgery-100640623","NCT07592091","Rectus Sheath Block Versus Transversus Abdominis Plane Block for Analgesia in Laparoscopic Bariatric Surgery","Comparison of Rectus Sheath Block and Transversus Abdominis Plane Block for Analgesia in Laparoscopic Bariatric Surgery: A Randomized Controlled Trial","RSB-TAPB","Inclusion Criteria:\n\n* Patients aged 20-60 years old\n* Scheduled for elective LBS including laparoscopic sleeve gastrectomy, proximal jejunal bypass, and Roux-en-Y gastric bypass\n* American Society of Anesthesia (ASA) physical status III\n* Have ability to communicate and understand the study and accept to participate in the study\n\nExclusion Criteria:\n\n* Patients who have following underlying disease: severe hepatic impairment \\[diagnosed of cirrhosis (Child-Pugh C)\\], coagulopathy (diagnosed of disease associated with abnormal coagulation), pre-existing neurological deficits, chronic pain (diagnosed of chronic pain disease or current use regular analgesic drugs), or any drug addiction.\n* Known allergy to bupivacaine or weighing less than 60 kg, as the planned doses of bupivacaine may exceed safe maximum limits.\n* Patient with previous foregut surgery including esophageal, gastric, liver and pancreases resection.","20 Years","60 Years",{"count":216,"type":19},96,[56],"This randomized controlled trial aims to compare the analgesic efficacy of rectus sheath block (RSB) and transversus abdominis plane block (TAPB) in patients undergoing laparoscopic bariatric surgery. Both techniques are regional anesthesia methods used as part of multimodal analgesia to reduce postoperative pain and opioid requirements.\n\nEligible participants will be randomly assigned to receive either a RSB or a TAPB after general anesthesia. Postoperative pain scores, opioid consumption, recovery outcomes, area of sensory loss, time to first rescue analgesia, and block-related adverse events will be assessed and compared between the two groups.\n\nThis study will help determine which regional anesthesia technique provides more effective postoperative analgesia for laparoscopic bariatric surgery",[220,221,25,61],"Rectus Sheath Block","Transverse Abdominis Plane Block",[220,223,224,225,226],"Transversus abdominis plane block","Laparoscopic bariatric surgery","opioid consumption","analgesia","2026-05-13",{"date":229,"type":34},"2026-05-18",{"date":231,"type":19},"2026-05-10",{"date":233,"type":19},"2031-06-30",{"name":235,"class":41},"Chiang Mai University",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":149,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":20,"phases":245,"briefSummary":246,"conditions":247,"keywords":253,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":263,"locationsCount":42},"100579224","comparison-of-pain-relief-methods-for-hip-surgery-a-study-on-two-different-nerve-block-techniques-100579224","NCT06821516","Comparison of Pain Relief Methods for Hip Surgery: A Study on Two Different Nerve Block Techniques","Comparison of Analgesic Effectiveness Between Pericapsular Nerve Group (PENG) Block and Lumbar Erector Spinae Plane Block in Patients Undergoing Total Hip Arthroplasty With Spinal Anesthesia: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Voluntary willingness to participate in the study.\n* Patients who will undergo Total Hip Arthroplasty surgery.\n* Patients aged over 18 years.\n* ASA score I-II-III.\n* Patients who are fully oriented and can cooperate.\n\nExclusion Criteria:\n\n* ASA score IV-V.\n* Patients who refuse to participate in the study.\n* Patients under 18 years of age.\n* Presence of active infection in the area to be operated on.\n* Chronic pain and continuous analgesic use.\n* Patients with coagulation disorders.\n* Patients who cannot cooperate with postoperative pain follow-up.\n* Patients with allergies to local anesthetic agents.\n* Presence of neuropathy or myopathy in the operated extremity.",{"count":244,"type":19},52,[56],"This prospective randomized comparative study aims to compare the analgesic efficacy of pericapsular nerve group block (PENG) and lumbar erector spinae plane block (L-ESP) groups to relieve postoperative pain in participants over the age of 18 undergoing total hip arthroplasty under spinal anesthesia. The main question it aims to answer is:\n\nTo demonstrate whether PENG block or L-ESP block is more effective in postoperative analgesia in patients undergoing total hip arthroplasty surgery based on pain scores, opioid consumption, and patient satisfaction.\n\nTotal hip arthroplasties cause severe pain with movement in the postoperative period. After surgery, the movements of the participants are severely restricted, which increases the possibility of complications. In this study, the participants' pain status, VAS score, opioid consumption through patient-controlled analgesia, and patient satisfaction will be measured with a questionnaire for 24 hours at predetermined time points and then compared. Both types of blocks have pain-relieving effects. This study will only investigate which one is more effective in reducing pain, and there will be no deficiency in relieving the pain of the participants.",[25,248,62,249,250,251,252],"Pain, Postoperative","PENG Block","Lumbar Erector Spinae Plane Block","Hip Replacement, Total","Postoperative Analgesia",[254,250,255,256],"Pericapsular Nerve Group (PENG) Block","Total Hip Arthroplasty","Postoperative analgesia","2026-05-01",{"date":259,"type":34},"2026-05-07",{"date":261,"type":34},"2025-01-21",{"date":137,"type":19},{"name":264,"class":265},"Başakşehir Çam & Sakura City Hospital","OTHER_GOV",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":214,"enrollmentInfo":274,"targetDuration":4,"studyType":20,"phases":276,"briefSummary":277,"conditions":278,"keywords":284,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":291,"leadSponsor":293,"locationsCount":42},"100635473","effect-of-preoperative-melatonin-on-quality-of-recovery-after-elective-laparoscopic-cholecystectomy-100635473","NCT07553143","Effect of Preoperative Melatonin on Quality of Recovery After Elective Laparoscopic Cholecystectomy","Effect of Preoperative Melatonin on Quality of Recovery After Elective Laparoscopic Cholecystectomy: A Randomized Controlled Trial","MEL-REC","Inclusion Criteria:\n\n* Age 18-60 years\n* American Society of Anesthesiologists (ASA) physical status I-II\n* Scheduled for elective laparoscopic cholecystectomy under general anesthesia\n* Able to understand and provide informed consent\n* Willing to participate in the study and complete follow-up assessments\n* Body mass index (BMI) 18-35 kg\u002Fm2\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to melatonin or placebo component\n* Chronic use of opioids, sedatives, or hypnotics (regular use for ≥4 weeks prior to surgery)\n* Current use of beta-adrenergic receptor antagonists (beta-blockers) (suppress endogenous melatonin secretion via inhibition of pineal β₁-adrenergic receptors)\n* History of psychiatric disorders requiring ongoing pharmacological treatment\n* Pregnancy or lactation\n* Severe hepatic impairment (Child-Pugh class B or C), as melatonin undergoes extensive first-pass hepatic metabolism via CYP1A2\n* Diagnosed obstructive sleep apnoea requiring continuous positive airway pressure\n* Diagnosed circadian rhythm disorder (e.g., delayed sleep phase disorder, advanced sleep phase disorder) requiring medical management\n* Use of exogenous melatonin supplements within 30 days prior to surgery\n* Inability to complete study questionnaires due to language barrier or cognitive impairment\n* History of substance abuse or dependence",{"count":275,"type":19},84,[56],"Laparoscopic cholecystectomy is one of the most commonly performed abdominal surgical procedures worldwide. Although the widespread implementation of Enhanced Recovery after Surgery (ERAS) protocols has improved perioperative outcomes, many patients continue to experience postoperative pain, sleep disturbance, anxiety, nausea, and fatigue, symptoms that collectively impair overall quality of recovery (QoR). Melatonin, an endogenous hormone that regulates circadian rhythm, also possesses anxiolytic, analgesic, antioxidant, and anti-inflammatory properties, positioning it as a valuable perioperative adjunct. However, most previous studies have evaluated melatonin primarily for isolated outcomes such as sleep quality or anxiety. Its effect on comprehensive postoperative recovery, assessed using validated patient-reported outcome instruments, remains insufficiently explored, particularly in laparoscopic cholecystectomy populations and in South Asian clinical settings.\n\nThis prospective, randomized, double-blind, placebo-controlled trial (the MEL-REC trial) aims to evaluate the effect of preoperative oral melatonin on postoperative quality of recovery in patients undergoing elective laparoscopic cholecystectomy under general anaesthesia. The study will be conducted in the Department of Anaesthesiology at Combined Military Hospital (CMH), Dhaka, Bangladesh, over a total study period of 18 months (January 2026 to June 2027), with patient recruitment planned for 8 months (May to December 2026) after taking approval from institutional review board. Eighty four adult patients aged 18-60 years with American Society of Anesthesiologists (ASA) physical status I-II will be randomly allocated in a 1:1 ratio into two equal groups (n = 42 per group) using computer-generated permuted block randomization with centralized pharmacy based allocation concealment. The melatonin group (Group M) will receive oral melatonin 6 mg administered 60 minutes before induction of anaesthesia and the placebo group (Group P) will receive an identical placebo tablet under the same conditions. Neither the participants, the treating anaesthesiologist, the outcome assessor, nor the data analyst will be aware of group allocation until database lock. All patients will receive a standardized anaesthesia and perioperative management protocol, including standardized postoperative analgesia.\n\nThe primary outcome will be postoperative quality of recovery assessed using the Quality of Recovery-15 (QoR-15) score at 24 ± 2 hours after surgery. Secondary outcomes include postoperative sleep quality measured by the Richards-Campbell Sleep Questionnaire, change in preoperative anxiety (delta-VAS-A score), total opioid consumption during the first 24 hours expressed as intravenous morphine milligram equivalents, incidence of postoperative nausea and vomiting, and time to first rescue analgesic request. All postoperative outcomes will be assessed by a trained research assistant blinded to group allocation.\n\nBased on the available evidence, it is anticipated that patients receiving preoperative melatonin will demonstrate higher QoR-15 scores at 24 hours after surgery compared with the placebo group. The melatonin group is also expected to have improved postoperative sleep quality, reduced opioid consumption, and a greater reduction in preoperative anxiety.\n\nIf a clinically meaningful benefit is confirmed, given its well established safety profile, low cost, and ease of oral administration, preoperative melatonin may represent a practical perioperative adjunct that can be readily incorporated into ERAS protocols for laparoscopic cholecystectomy. The trial will be prospectively registered in the Bangladesh Medical Research Council (BMRC) clinical trial registry or clinicaltrials.gov prior to recruitment.",[279,280,281,282,25,283],"Laparoscopic Cholecystectomy","Postoperative Quality of Recovery","Preoperative Anxiety","Postoperative Sleep Quality","PONV in Laparoscopic Cholocystectomies",[280,285,286,279],"QoR-15","Melatonin","2026-04-29",{"date":289,"type":34},"2026-05-05",{"date":257,"type":19},{"date":292,"type":19},"2027-06-30",{"name":294,"class":41},"Armed Forces Medical Institute Bangladesh",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":51,"minAge":16,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":20,"phases":305,"briefSummary":306,"conditions":307,"keywords":310,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":322,"leadSponsor":324,"locationsCount":42},"100634055","phase-4-suzetrigine-for-opioid-free-recovery-after-cesarean-delivery-100634055","NCT07534709","Suzetrigine for Opioid-Free Recovery After Cesarean Delivery","Suzetrigine Versus Placebo for Opioid-Free Recovery After Cesarean Delivery: A Randomized Controlled Trial","SPARE","Inclusion Criteria:\n\n* Women aged ≥18 years.\n* Undergoing scheduled or unscheduled cesarean delivery during the current admission, with or without concomitant salpingectomy.\n* Planned delivery under neuraxial anesthesia (spinal, epidural, or combined spinal-epidural).\n* Planned Pfannenstiel skin incision.\n* Able to provide informed consent in English or Spanish.\n* Willing and able to complete required remote follow-up assessments through postoperative day 14 (POD14).\n\nExclusion Criteria:\n\n* Planned provision of breast milk to the neonate during the period of suzetrigine exposure (while the study drug is being taken and for 96 hours after last dose), due to the absence of human lactation safety data for suzetrigine.\\*\n* Known allergy, hypersensitivity, or contraindication to suzetrigine or any component of its formulation.\n* Chronic opioid use, defined as daily opioid use for more than 7 consecutive days in the month prior to delivery, or current treatment for opioid use disorder.\n* Significant hepatic disease, defined as AST or ALT \\>3 times the upper limit of normal or Child-Pugh class B or C.\n* Severe renal impairment, defined as estimated glomerular filtration rate (eGFR) \\\u003C15 mL\u002Fmin.\n* Concurrent use of medications known to significantly alter suzetrigine metabolism, including strong CYP3A inhibitors or inducers, such as:\n\n  * ketoconazole\n  * ritonavir\n  * carbamazepine\n  * rifampin\n  * St. John's wort (or other agents deemed clinically significant CYP3A modulators by the study investigator team)\n* Planned cesarean delivery under general anesthesia without neuraxial anesthesia.\n* Planned non-Pfannenstiel skin incision (e.g., vertical midline incision).\n* Participation in another interventional pain-management clinical trial during the current hospitalization.\n* Additional operative procedures (excluding salpingectomy) performed at the time of cesarean delivery (e.g., hysterectomy, hernia repair).\n* Inability to provide informed consent or to complete required study procedures and follow-up.\n* Receipt of opioid or sedating medications prior to completion of the informed consent process.\n\n  * Feeding decisions are made independently of study participation. The study does not require participants to alter infant feeding plans; eligibility is determined solely by whether breast milk will be provided to the neonate during the period of study drug exposure (while the study drug is being taken and for 96 hours after last dose). Participants who plan to breastfeed but independently elect not to provide breast milk to the neonate during the period of suzetrigine exposure are eligible.",{"count":304,"type":19},90,[22],"The goal of this clinical trial is to determine whether suzetrigine increases the proportion of patients who remain completely opioid-free from completion of surgery through 72 hours after cesarean delivery.\n\nThe main question it aims to answer is:\n\nDoes adjunctive suzetrigine, when added to a standardized multimodal postoperative analgesic regimen, increase the proportion of patients who remain opioid-free during the first 72 hours after cesarean delivery?\n\nResearchers will compare suzetrigine to a placebo (a look-alike substance that contains no drug) to evaluate this outcome.\n\nParticipants will:\n\n* Receive either suzetrigine or placebo after cesarean delivery\n* Receive standard postoperative pain management, including acetaminophen, nonsteroidal anti-inflammatory drugs, and neuraxial morphine\n* Have opioid medications available as needed for breakthrough pain\n* Be followed during hospitalization and after discharge to assess pain, recovery, and medication use",[308,309,248,25],"Cesarean Delivery","Cesarean Section",[311,308,312,29,313,314,315,316,317],"suzetrigine","cesarean section","opioid-free recovery","opioid-sparing","multimodal analgesia","postpartum opioid use","NaV1.8 Inhibitor","2026-04-14",{"date":320,"type":34},"2026-04-16",{"date":36,"type":19},{"date":323,"type":19},"2028-05",{"name":325,"class":41},"University of Texas at Austin",{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":20,"phases":335,"briefSummary":336,"conditions":337,"keywords":340,"overallStatus":132,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":42},"100609992","preoperative-opioid-tapering-before-spine-surgery-100609992","NCT07221786","Preoperative Opioid Tapering Before Spine Surgery","A Pilot Study of the Feasibility of Preoperative Opioid Tapering Before Spine Surgery Using Cognitive Behavioral Therapy and Measuring Postoperative Outcomes","Inclusion:\n\n* at least 18 years old\n* scheduled for major spine surgery (i.e. at least 1 level of fusion) with hospital admission of at least one night\n* scheduled for spine surgery at least 4 weeks ahead of time\n* takes between 40 and 200 oral morphine equivalents daily\n\nExclusion:\n\n* inability to use a computer or tablet for telemedicine encounters\n* non-English-speaking\n* inability to complete assessments\n* positive screen on the Columbia Suicide Screening Assessment",{"count":334,"type":19},45,[56],"This is a pilot study in which patients taking opioids chronically who are scheduled for spine surgery at least 4 weeks in advance will be randomly assigned to one of two groups: opioid tapering with education alone or opioid tapering with education plus cognitive behavioral therapy (CBT). The primary objective is to determine the proportion of each group that is successful in achieving their opioid tapering goals by the time of surgery.",[25,338,339],"Pain After Surgery","Opioid Dependency",[341,342,343,344,345,346,347,348,349],"spine surgery","pain management","opioids","opioid use","depression","anxiety","opioid dependence","opioid tapering","cognitive behavioral therapy","2026-03-23",{"date":352,"type":34},"2026-03-24",{"date":354,"type":34},"2025-12-01",{"date":356,"type":19},"2026-12",{"name":358,"class":41},"Thomas Jefferson University",{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":365,"eligibilityCriteria":366,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":20,"phases":369,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":42},"100610217","phase-4-the-impact-of-perioperative-lidocaine-infusions-on-enhanced-recovery-after-non-cardiac-surgery-100610217","NCT07224711","The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery","The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery (IMPALA ERAS)","IMPALA ERAS","Inclusion criteria:\n\n* Age greater than or equal to 18\n* American Society of Anesthesiologists (ASA) class II-IV\n* Presenting for major elective, non-cardiac surgery on the colorectal, emergency general surgery, urology, ventral hernia, surgical oncology, or spine services on a weekday\n* First surgery in the study period (if a patient has multiple surgeries, only the first will be included)\n\nExclusion criteria:\n\n* ASA class \\>IV\n* Emergent procedures\n* Allergy or any contraindication to lidocaine infusion\n* Patient refusal\n* Unable to receive or refusal to receive a regional nerve block\n* Patients who receive an epidural due to standard of care\n* Direct transfer from operating room to ICU with endotracheal tube in place\n* Treating team determines patient ineligible prior to study drug administration\n* Same day surgery\n* Pregnancy (all female patient of child-bearing age will undergo a pregnancy test the day of surgery)",{"count":368,"type":19},2290,[22],"The goal of this single-center, pragmatic, randomized, blinded, placebo-controlled trial is to evaluate the impact of intravenous (IV) lidocaine within the existing Enhanced Recovery After Surgery (ERAS)program on outcomes in patients after major non-cardiac surgery. The main questions the trial aims to answer are:\n\nThe primary hypothesis is that utilization of IV lidocaine as part of a perioperative multimodal pain regimen will result in a reduction in hospital Case Mix Index-Adjusted Resource Length of Stay (CARLOS).\n\nThe secondary hypotheses are that lidocaine infusion will result in a reduction in total inpatient opioid consumption (oral morphine milligram equivalents, oMMEs) and pain scores, and improved surgical outcomes (including return of bowel function, ileus, nausea, rapid responses called, surgical site infections, and ICU transfers), while also having minimal incidence of side effects (including double\u002Fblurry vision, tinnitus, sedation, and adverse events requiring early cessation).",[162,372,25],"Post Operative Analgesia","2026-03-18",{"date":375,"type":34},"2026-03-20",{"date":377,"type":19},"2026-07-01",{"date":379,"type":19},"2028-05-30",{"name":381,"class":41},"Vanderbilt University Medical Center",{"id":383,"slug":384,"hasResults":11,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":388,"eligibilityCriteria":389,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":390,"enrollmentInfo":391,"targetDuration":4,"studyType":20,"phases":393,"briefSummary":394,"conditions":395,"keywords":396,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":4},"100613175","dexmedetomidine-as-an-adjuvant-to-bupivacaine-for-ultrasound-guided-external-oblique-intercostal-block-100613175","NCT07263165","Dexmedetomidine as an Adjuvant to Bupivacaine for Ultrasound-Guided External Oblique Intercostal Block","Effect of Adding Dexmedetomidine as Adjuvant to Bupivacaine in Ultrasound Guided External Oblique Intercostal Plane Block in Upper Abdominal Cancer Surgery. A Prospective Randomized Clinical Trial","Dexmedetomidin","Inclusion Criteria:\n\n* Patients aged 18-70 years scheduled for elective upper abdominal cancer surgery (e.g., gastrectomy, hepatectomy, pancreatectomy).\n* American Society of Anesthesiologists (ASA) physical status I-III.\n* Body mass index (BMI) between 18-35 kg\u002Fm².\n\nExclusion Criteria:\n\n* Patient refusal.\n* Allergy to local anesthetics or dexmedetomidine.\n* Coagulopathy (INR \\>1.5, platelet count \\\u003C100,000\u002Fmm³).\n* Infection at the injection site.\n* Severe cardiopulmonary, renal, or hepatic dysfunction.\n* Chronic opioid use (\\>30 mg morphine equivalents daily for \\>3 months).\n* Pregnancy or lactation.","70 Years",{"count":392,"type":19},54,[56],"Effect of Adding Dexmedetomidine as Adjuvant toBupivacaine in Ultrasound Guided ExternalOblique Intercostal Plane Block in UpperAbdominal Cancer Surgery.",[25],[397,398],"dexmedetomidine","external oblique intercostal block","2025-11-23",{"date":401,"type":34},"2025-12-04",{"date":403,"type":19},"2025-12-15",{"date":405,"type":19},"2027-12-15",{"name":407,"class":41},"Assiut University",{"id":409,"slug":410,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":20,"phases":418,"briefSummary":419,"conditions":420,"keywords":429,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":42},"100587065","phase-4-intravenous-acetaminophen-to-reduce-post-operative-opioid-consumption-100587065","NCT06923540","Intravenous Acetaminophen to Reduce Post-operative Opioid Consumption","Evaluating the Impact of IV Acetaminophen on Opioid Consumption in the Postoperative Period in Patients Undergoing Abdominal Surgery","ACETAPOP","Inclusion Criteria:\n\n* Age 18 years or older.\n* Underwent abdominal surgery\n* Underwent elective surgery.\n* Hospitalized in the digestive surgery, hepatobiliary and pancreatic surgery, or gynecology and gynecologic oncology units at CHUM.\n* Declared NPO immediately post-surgery, meaning they cannot take oral medications.\n\nExclusion Criteria:\n\n* Hypersensitivity to acetaminophen or an excipient in the administered formulations\n* Hepatic insufficiency with a Child-Turcotte-Pugh score of B or C.\n* Weight \\\u003C 50 kg (patients requiring a lower acetaminophen dose).\n* Active pregnancy or breastfeeding.\n* Opioid use disorder (OUD) under active treatment\n* Non-opioid-naïve patients: those who received a long-acting opioid within seven days preceding surgery. This criterion will be verified through patient interviews and cross-checked with medical records.\n* Use of illicit recreational substances.\n* Prior participation in this study.\n* Ectopic patients: physically located in a unit other than digestive surgery (11 South), hepatobiliary and pancreatic surgery (14 South), or gynecology and gynecologic oncology (12 South).",{"count":417,"type":19},140,[22],"Acetaminophen (Tylenol) is a commonly used medication after surgery to control pain. Tablets for oral use and suppositories for rectal use are the most frequently employed forms of acetaminophen after surgery. Intravenous (IV) acetaminophen is widely used in several countries but is not a standard medication for the adult population in Canada. It is mainly considered when it is impossible to take medication in tablet or suppository form. Opioids (Morphine, Hydromorphone, Oxycodone, etc.) are another class of medications commonly used after surgery for pain management. While they are generally very effective and stronger than acetaminophen or other pain relievers (e.g., ibuprofen\u002FAdvil), reducing their use is preferable, as they can cause various side effects such as nausea, dizziness, and dependence. IV acetaminophen may help control pain while also reducing opioid consumption. However, there are few high-quality scientific studies proving the benefits of IV acetaminophen compared to other forms, such as tablets or suppositories. Acetaminophen has been available in Canada for many years and has already been recommended for use in Quebec by the Institut national d'excellence en santé et services sociaux (INESSS) under certain conditions. This study aims to validate its benefits with clear data.",[372,25,421,422,423,424,425,426,427,428,130],"Acetaminophen","Abdominal Surgeries","Post Operative Bowel Dysfunction","Post Operative Nausea and Vomiting","Post Operative Pain Control","Mobility","Epidural Analgesia","Length of Stay",[430,431,432,433,434,435,436,225,437,438,439,440,441,442,443,444,445],"IV acetaminophen","intravenous acetaminophen","acetaminophen","post operative analgesia","nil per os","npo","post operative pain","abdominal surgery","hepato-biliary surgery","digestive surgery","pancreatic surgery","gynecologic surgery","post operative nausea and vomiting","post operative mobility","hospitalization length of stay","co-analgesia","2025-04-04",{"date":448,"type":34},"2025-04-11",{"date":450,"type":19},"2025-04-28",{"date":452,"type":19},"2025-08-15",{"name":454,"class":41},"Centre hospitalier de l'Université de Montréal (CHUM)"]